Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: Expert panel review

Jorge E. Cortes, Jane F. Apperley, Daniel J. Deangelo, Michael W. Deininger, Vamsi Kota, Philippe Rousselot, Carlo Gambacorti-Passerini

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Bosutinib, a BCR-ABL1 tyrosine kinase inhibitor (TKI), has been available for several years as a treatment for chronic-, accelerated-, and blast-phase chronic myeloid leukemia (CML), for patients with resistance or intolerance to prior therapy. In 2017, the BFORE trial demonstrated efficacy of bosutinib as first-line treatment in adult patients with newly diagnosed chronic-phase chronic myeloid leukemia (CP-CML). The most common adverse events (AEs) of any grade in bosutinib-treated patients in BFORE were diarrhea, nausea, thrombocytopenia, increased alanine aminotransferase, and increased aspartate aminotransferase, consistent with the most commonly reported AEs in earlier studies. To balance the efficacy and tolerability of treatment to optimize patient adherence with medications, treating physicians commonly use various strategies such as initiating treatment at a lower dose, dose reduction, or dose interruption, depending on the type and severity of the AEs and the clinical setting. In light of the recent data from first-line treatment, an expert panel of hematologists reviewed management strategies for the use of bosutinib in treatment of CP-CML and made the recommendations reported here. Although the panel focused on first-line treatment, the principles can be for the most part extended to bosutinib use in later lines of treatment. Recommendations include advice regarding prophylaxis and management for diarrhea. The panel also considered optimum timing for referral to a specialist for specific AEs. Across the commonly occurring AEs, the panel highlighted the importance of education and communication with patients about anticipated AEs.

Original languageEnglish (US)
Article number143
JournalJournal of Hematology and Oncology
Volume11
Issue number1
DOIs
StatePublished - Dec 27 2018

Fingerprint

Leukemia, Myeloid, Chronic Phase
Therapeutics
Leukemia, Myeloid, Accelerated Phase
Diarrhea
Blast Crisis
bosutinib
Patient Compliance
Aspartate Aminotransferases
Alanine Transaminase
Thrombocytopenia
Protein-Tyrosine Kinases
Nausea
Referral and Consultation
Communication
Physicians
Education

Keywords

  • Adverse events
  • Bosutinib
  • Chronic myeloid leukemia
  • Dosing strategies
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Molecular Biology
  • Hematology
  • Oncology
  • Cancer Research

Cite this

Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia : Expert panel review. / Cortes, Jorge E.; Apperley, Jane F.; Deangelo, Daniel J.; Deininger, Michael W.; Kota, Vamsi; Rousselot, Philippe; Gambacorti-Passerini, Carlo.

In: Journal of Hematology and Oncology, Vol. 11, No. 1, 143, 27.12.2018.

Research output: Contribution to journalReview article

Cortes, Jorge E. ; Apperley, Jane F. ; Deangelo, Daniel J. ; Deininger, Michael W. ; Kota, Vamsi ; Rousselot, Philippe ; Gambacorti-Passerini, Carlo. / Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia : Expert panel review. In: Journal of Hematology and Oncology. 2018 ; Vol. 11, No. 1.
@article{2b1b821dd86f47c797d6c2d2d942bfa7,
title = "Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: Expert panel review",
abstract = "Bosutinib, a BCR-ABL1 tyrosine kinase inhibitor (TKI), has been available for several years as a treatment for chronic-, accelerated-, and blast-phase chronic myeloid leukemia (CML), for patients with resistance or intolerance to prior therapy. In 2017, the BFORE trial demonstrated efficacy of bosutinib as first-line treatment in adult patients with newly diagnosed chronic-phase chronic myeloid leukemia (CP-CML). The most common adverse events (AEs) of any grade in bosutinib-treated patients in BFORE were diarrhea, nausea, thrombocytopenia, increased alanine aminotransferase, and increased aspartate aminotransferase, consistent with the most commonly reported AEs in earlier studies. To balance the efficacy and tolerability of treatment to optimize patient adherence with medications, treating physicians commonly use various strategies such as initiating treatment at a lower dose, dose reduction, or dose interruption, depending on the type and severity of the AEs and the clinical setting. In light of the recent data from first-line treatment, an expert panel of hematologists reviewed management strategies for the use of bosutinib in treatment of CP-CML and made the recommendations reported here. Although the panel focused on first-line treatment, the principles can be for the most part extended to bosutinib use in later lines of treatment. Recommendations include advice regarding prophylaxis and management for diarrhea. The panel also considered optimum timing for referral to a specialist for specific AEs. Across the commonly occurring AEs, the panel highlighted the importance of education and communication with patients about anticipated AEs.",
keywords = "Adverse events, Bosutinib, Chronic myeloid leukemia, Dosing strategies, Tyrosine kinase inhibitor",
author = "Cortes, {Jorge E.} and Apperley, {Jane F.} and Deangelo, {Daniel J.} and Deininger, {Michael W.} and Vamsi Kota and Philippe Rousselot and Carlo Gambacorti-Passerini",
year = "2018",
month = "12",
day = "27",
doi = "10.1186/s13045-018-0685-2",
language = "English (US)",
volume = "11",
journal = "Journal of Hematology and Oncology",
issn = "1756-8722",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia

T2 - Expert panel review

AU - Cortes, Jorge E.

AU - Apperley, Jane F.

AU - Deangelo, Daniel J.

AU - Deininger, Michael W.

AU - Kota, Vamsi

AU - Rousselot, Philippe

AU - Gambacorti-Passerini, Carlo

PY - 2018/12/27

Y1 - 2018/12/27

N2 - Bosutinib, a BCR-ABL1 tyrosine kinase inhibitor (TKI), has been available for several years as a treatment for chronic-, accelerated-, and blast-phase chronic myeloid leukemia (CML), for patients with resistance or intolerance to prior therapy. In 2017, the BFORE trial demonstrated efficacy of bosutinib as first-line treatment in adult patients with newly diagnosed chronic-phase chronic myeloid leukemia (CP-CML). The most common adverse events (AEs) of any grade in bosutinib-treated patients in BFORE were diarrhea, nausea, thrombocytopenia, increased alanine aminotransferase, and increased aspartate aminotransferase, consistent with the most commonly reported AEs in earlier studies. To balance the efficacy and tolerability of treatment to optimize patient adherence with medications, treating physicians commonly use various strategies such as initiating treatment at a lower dose, dose reduction, or dose interruption, depending on the type and severity of the AEs and the clinical setting. In light of the recent data from first-line treatment, an expert panel of hematologists reviewed management strategies for the use of bosutinib in treatment of CP-CML and made the recommendations reported here. Although the panel focused on first-line treatment, the principles can be for the most part extended to bosutinib use in later lines of treatment. Recommendations include advice regarding prophylaxis and management for diarrhea. The panel also considered optimum timing for referral to a specialist for specific AEs. Across the commonly occurring AEs, the panel highlighted the importance of education and communication with patients about anticipated AEs.

AB - Bosutinib, a BCR-ABL1 tyrosine kinase inhibitor (TKI), has been available for several years as a treatment for chronic-, accelerated-, and blast-phase chronic myeloid leukemia (CML), for patients with resistance or intolerance to prior therapy. In 2017, the BFORE trial demonstrated efficacy of bosutinib as first-line treatment in adult patients with newly diagnosed chronic-phase chronic myeloid leukemia (CP-CML). The most common adverse events (AEs) of any grade in bosutinib-treated patients in BFORE were diarrhea, nausea, thrombocytopenia, increased alanine aminotransferase, and increased aspartate aminotransferase, consistent with the most commonly reported AEs in earlier studies. To balance the efficacy and tolerability of treatment to optimize patient adherence with medications, treating physicians commonly use various strategies such as initiating treatment at a lower dose, dose reduction, or dose interruption, depending on the type and severity of the AEs and the clinical setting. In light of the recent data from first-line treatment, an expert panel of hematologists reviewed management strategies for the use of bosutinib in treatment of CP-CML and made the recommendations reported here. Although the panel focused on first-line treatment, the principles can be for the most part extended to bosutinib use in later lines of treatment. Recommendations include advice regarding prophylaxis and management for diarrhea. The panel also considered optimum timing for referral to a specialist for specific AEs. Across the commonly occurring AEs, the panel highlighted the importance of education and communication with patients about anticipated AEs.

KW - Adverse events

KW - Bosutinib

KW - Chronic myeloid leukemia

KW - Dosing strategies

KW - Tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=85059236842&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059236842&partnerID=8YFLogxK

U2 - 10.1186/s13045-018-0685-2

DO - 10.1186/s13045-018-0685-2

M3 - Review article

C2 - 30587215

AN - SCOPUS:85059236842

VL - 11

JO - Journal of Hematology and Oncology

JF - Journal of Hematology and Oncology

SN - 1756-8722

IS - 1

M1 - 143

ER -